UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Meredith C Henderson
1
,
Yeng Jeng Y Shaw
2
,
Hong Wang
3
,
Haiyong Han
3
,
Laurence H. Hurley
1, 2, 4
,
GARY FLYNN
2
,
ROBERT T. DORR
1, 4
,
Daniel D. Von Hoff
3
1
1Arizona Cancer Center,
|
2
2BIO5 Institute, and
3
4Translational Genomics Research Institute, Phoenix, Arizona
|
Publication type: Journal Article
Publication date: 2009-01-01
scimago Q1
wos Q1
SJR: 2.493
CiteScore: 11.0
Impact factor: 5.5
ISSN: 15357163, 15388514
PubMed ID:
19139111
Cancer Research
Oncology
Abstract
Pancreatic carcinoma is the fourth leading cause of death from cancer. Novel targets and therapeutic options are needed to aid in the treatment of pancreatic cancer. The compound UA62784 is a novel fluorenone with inhibitory activity against the centromere protein E (CENP-E) kinesin-like protein. UA62784 was isolated due to its selectivity in isogenic pancreatic carcinoma cell lines with a deletion of the DPC4 gene. UA62784 causes mitotic arrest by inhibiting chromosome congression at the metaphase plate likely through inhibition of the microtubule-associated ATPase activity of CENP-E. Furthermore, CENP-E binding to kinetochores during mitosis is not affected by UA62784, suggesting that the target lies within the motor domain of CENP-E. UA62784 is a novel specific inhibitor of CENP-E and its activity suggests a potential role for antimitotic drugs in treating pancreatic carcinomas. [Mol Cancer Ther 2009;8(1):36–44]
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
PLoS ONE
3 publications, 8.57%
|
|
|
Chemistry & Biology
3 publications, 8.57%
|
|
|
Journal of Pharmacology and Experimental Therapeutics
1 publication, 2.86%
|
|
|
Pharmacological Reviews
1 publication, 2.86%
|
|
|
Anti-Cancer Agents in Medicinal Chemistry
1 publication, 2.86%
|
|
|
Journal of Cell Science
1 publication, 2.86%
|
|
|
Biology
1 publication, 2.86%
|
|
|
Pharmaceutical Research
1 publication, 2.86%
|
|
|
Investigational New Drugs
1 publication, 2.86%
|
|
|
Chromosoma
1 publication, 2.86%
|
|
|
Molecular Biology Reports
1 publication, 2.86%
|
|
|
Cancer Chemotherapy and Pharmacology
1 publication, 2.86%
|
|
|
Seminars in Cell and Developmental Biology
1 publication, 2.86%
|
|
|
Cancer Letters
1 publication, 2.86%
|
|
|
Biochimica et Biophysica Acta - General Subjects
1 publication, 2.86%
|
|
|
Current Biology
1 publication, 2.86%
|
|
|
Cancer Treatment Reviews
1 publication, 2.86%
|
|
|
Clinics
1 publication, 2.86%
|
|
|
Life Sciences
1 publication, 2.86%
|
|
|
Pediatric Blood and Cancer
1 publication, 2.86%
|
|
|
Journal of Cellular Biochemistry
1 publication, 2.86%
|
|
|
ChemPlusChem
1 publication, 2.86%
|
|
|
Journal of Physical Chemistry B
1 publication, 2.86%
|
|
|
Journal of Natural Products
1 publication, 2.86%
|
|
|
Angewandte Chemie - International Edition
1 publication, 2.86%
|
|
|
Molecular Cancer Therapeutics
1 publication, 2.86%
|
|
|
Canadian Journal of Chemistry
1 publication, 2.86%
|
|
|
Frontiers in Molecular Biosciences
1 publication, 2.86%
|
|
|
Journal of Hepatology
1 publication, 2.86%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
12
|
|
|
Elsevier
11 publications, 31.43%
|
|
|
Springer Nature
5 publications, 14.29%
|
|
|
Wiley
4 publications, 11.43%
|
|
|
Public Library of Science (PLoS)
3 publications, 8.57%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
2 publications, 5.71%
|
|
|
American Chemical Society (ACS)
2 publications, 5.71%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 2.86%
|
|
|
The Company of Biologists
1 publication, 2.86%
|
|
|
MDPI
1 publication, 2.86%
|
|
|
1 publication, 2.86%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 2.86%
|
|
|
Canadian Science Publishing
1 publication, 2.86%
|
|
|
Frontiers Media S.A.
1 publication, 2.86%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
35
Total citations:
35
Citations from 2024:
4
(11.42%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Henderson M. C. et al. UA62784, a novel inhibitor of centromere protein E kinesin-like protein // Molecular Cancer Therapeutics. 2009. Vol. 8. No. 1. pp. 36-44.
GOST all authors (up to 50)
Copy
Henderson M. C., Shaw Y. J. Y., Wang H., Han H., Hurley L. H., FLYNN G., DORR R. T., Von Hoff D. D. UA62784, a novel inhibitor of centromere protein E kinesin-like protein // Molecular Cancer Therapeutics. 2009. Vol. 8. No. 1. pp. 36-44.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1158/1535-7163.mct-08-0789
UR - https://doi.org/10.1158/1535-7163.mct-08-0789
TI - UA62784, a novel inhibitor of centromere protein E kinesin-like protein
T2 - Molecular Cancer Therapeutics
AU - Henderson, Meredith C
AU - Shaw, Yeng Jeng Y
AU - Wang, Hong
AU - Han, Haiyong
AU - Hurley, Laurence H.
AU - FLYNN, GARY
AU - DORR, ROBERT T.
AU - Von Hoff, Daniel D.
PY - 2009
DA - 2009/01/01
PB - American Association for Cancer Research (AACR)
SP - 36-44
IS - 1
VL - 8
PMID - 19139111
SN - 1535-7163
SN - 1538-8514
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2009_Henderson,
author = {Meredith C Henderson and Yeng Jeng Y Shaw and Hong Wang and Haiyong Han and Laurence H. Hurley and GARY FLYNN and ROBERT T. DORR and Daniel D. Von Hoff},
title = {UA62784, a novel inhibitor of centromere protein E kinesin-like protein},
journal = {Molecular Cancer Therapeutics},
year = {2009},
volume = {8},
publisher = {American Association for Cancer Research (AACR)},
month = {jan},
url = {https://doi.org/10.1158/1535-7163.mct-08-0789},
number = {1},
pages = {36--44},
doi = {10.1158/1535-7163.mct-08-0789}
}
Cite this
MLA
Copy
Henderson, Meredith C., et al. “UA62784, a novel inhibitor of centromere protein E kinesin-like protein.” Molecular Cancer Therapeutics, vol. 8, no. 1, Jan. 2009, pp. 36-44. https://doi.org/10.1158/1535-7163.mct-08-0789.